BMS453 (1 μM; 11 hours; 184 and HMEC cells) treatment inhibits the proliferation of normal breast cell growth without significantly inducing apoptosis[2].
The RARβ-selective agonist (BMS453), but not RARα- or RARγ-selective agonists (BMS753 and BMS961, respectively), significantly reduced the T47D breast cancer cell migration to levels comparable to inhibition by RA, indicating that RARβ is involved in RA-inhibited cell migration[3].